Uncertainty and innovation: Understanding the role of cell-based manufacturing facilities in shaping regulatory and commercialization environments

Applied and Translational Genomics

Volumn 11, Issue , 2016, Pages 27-39

  Isasi, Rosario ^a   Rahimzadeh, Vasiliki ^b   Charlebois, Kathleen ^c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c ST MARY S HOSPITAL   (Canada)

Author keywords

Canada; Cell based therapies; Commercialization; Institutional change; Regenerative medicine; Regulation

Indexed keywords

ARTICLE; CANADA; CELL THERAPY; CLINICAL EFFECTIVENESS; COMMERCIAL PHENOMENA; CONCEPTUAL FRAMEWORK; CONFUSION (UNCERTAINTY); DESCRIPTIVE RESEARCH; EMPIRICAL RESEARCH; GOOD MANUFACTURING PRACTICE; HUMAN; MANUFACTURING INDUSTRY; PRIORITY JOURNAL; QUALITATIVE RESEARCH; REPRODUCIBILITY; SAFETY; STANDARD; TRANSLATIONAL RESEARCH;

EID: 85006342011     PISSN: 22120661     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atg.2016.11.001     Document Type: Article

References (33)

1. Abbasalizadeh, S., Baharvand, H., Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies. Biotechnol. Adv. 31:8 (2013), 1600–1623.
2. Anon, Food and Drugs Act, Canada. 1985.
3. Bailey, A.M., Mendicino, M., Au, P., An FDA perspective on preclinical development of cell-based regenerative medicine products. Nat. Biotechnol. 32:8 (2014), 721–723.
4. Beak, C., Isasi, R., Regenerative medicine: socio-ethical challenges and regulatory approaches. Joly, Y., Knoppers, B.M., (eds.) Routledge Handbook of Medical Law and Ethics, 2014, Routledge, New York, NY, 244–268.
5. Bowen, G.A., Naturalistic inquiry and the saturation concept: a research note. Qual. Res. 8:1 (2008), 137–152.
6. Brooks, J., et al. The utility of template analysis in qualitative psychology research. Qual. Res. Psychol. 12:2 (2014), 202–222.
7. Carlile, P.R., A pragmatic view of knowledge and boundaries: boundary objects in new product development. Organ. Sci. 13:4 (2002), 442–455.
8. Eriksson, L., Webster, A., Standardizing work as a recursive process: shaping the embryonic stem cell field. New Genet. Soc. 34:1 (2015), 72–88.
9. French, A., Buckler, R.L., Brindley, D.A., Commercialization of regenerative medicine: learning from spin-outs. Rejuvenation Res. 16:2 (2013), 164–170.
10. Ginty, P.J., et al. Regenerative medicine, resource and regulation: lessons learned from the remedi project. Regen. Med. 6:2 (2011), 241–253.
11. Heathman, T.R.J., et al. The translation of cell-based therapies: clinical landscape and manufacturing challenges. Regen. Med. 10:1 (2015), 49–64.
12. Isasi, R., Knoppers, B.M., From banking to international governance: fostering innovation in stem cell research. Stem Cells Int., 2011, 2011, 498132.
13. Isasi, R.M., Policy interoperability in stem cell research: demystifying harmonization. Stem Cell Rev. 5:2 (2009), 108–115.
14. Isasi, R.M., Knoppers, B.M., Governing stem cell banks and registries: emerging issues. Stem Cell Res. 3:2–3 (2009), 96–105.
15. Kuper, A., Lingard, L., Levinson, W., Critically appraising qualitative research. Br. Med. J., 337, 2008 a1035–a1035.
16. Lauckner, H., Paterson, M., Krupa, T., Using constructivist case study methodology to understand community development processes: proposed methodological questions to guide the research process. The Qualitative Report 2012, 17(Article 25), 2012, 1–22.
17. Levesque, M., et al. Stem cell research funding policies and dynamic innovation: a survey of open access and commercialization requirements. Stem Cell Rev. 10:4 (2014), 455–471.
18. Miles, M.B., Huberman, M.A., Saldaña, J., Qualitative data analysis. A methods sourcebook. Z. Pers. 28:4 (2014), 485–487.
19. Nature Editorials, Fetal tissue research under threat. Nature 528:December 10 (2015), 163–164.
20. Patton, M.Q., Qualitative Research and Evaluation Methods. fourth ed, 2014, SAGE Publications.
21. Patton, M.Q., Qualitative Research and Evaluation Methods: Theory and Practice. fourth ed, 2015, SAGE Publications, Saint Paul.
22. Ridgway, A., Stem cell research & therapy celebrates its fifth anniversary. 2015, BMC Blog Network.
23. Ritchie, J., Spencer, L., Qualitative data analysis for applied policy research. Huberman, M., Miles, M.B., (eds.) The Qualitative Researcher's Companion, 2002, SAGE Publications.
24. Robinson, O.C., Sampling in interview-based qualitative research: a theoretical and practical guide. Qual. Res. Psychol. 11:1 (2013), 25–41.
25. Rosemann, A., Standardization as situation-specific achievement: regulatory diversity and the production of value in intercontinental collaborations in stem cell medicine. Soc. Sci. Med. 122 (2014), 72–80.
26. Shenton, A., Strategies for ensuring trustworthiness in qualitative research projects. Educ. Inf. 22 (2004), 63–75.
27. Smets, M., Morris, T., Greenwood, R., From practice to field: a multilevel model of practice driven institutional change. Acad. Manag. J. 55:4 (2012), 877–904.
28. von Tigerstrom, B., Human tissue legislation and a new medical paradigm: governing tissue engineering in Canada. McGill J. Law Health 8:2 (2015), S1–S56.
29. Viswanathan, S., Bubela, T., Current practices and reform proposals for the regulation of advanced medicinal products in Canada. Regen. Med. 10:5 (2015), 647–663.
30. Von Tigerstom, B., Revising the regulation of stem cell-based therapies: critical assessment of potential models. Food Drug Law J. 70:2 (2015), 315–337.
31. Webster, A., Eriksson, L., Governance-by-standards in the field of stem cells: managing uncertainty in the world of “basic innovation” uncertainty in the world of “basic innovation”. New Genet. Soc. 27:2 (2008), 99–111.
32. Webster, A., Haddad, C., Waldby, C., Experimental heterogeneity and standardisation: stem cell products and the clinical trial process. BioSocieties 6:4 (2011), 401–419.
33. Zietsma, C., Lawrence, T.B., Institutional work in the transformation of an organizational field: the interplay of boundary work and practice work. Adm. Sci. Q. 55:2 (2010), 189–221.